

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/730,174	12/05/2000	Richard J. Zahradnik	IMUNE-001A	8045
7663	7590 06/15/2004		EXAMINER	
STETINA BRUNDA GARRED & BRUCKER 75 ENTERPRISE, SUITE 250 ALISO VIEJO, CA 92656			HUYNH, PHUONG N	
			ART UNIT	PAPER NUMBER
			1644	
		DATE MAILED: 06/15/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/730,174	ZAHRADNIK ET AL.			
		Examiner	Art Unit			
		Phuong Huynh	1644			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SH THE - Exter after - If the - If NO - Failu	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1: SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply or period for reply is specified above, the maximum statutory period or to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tim y within the statutory minimum of thirty (30) days vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	ely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on					
2a)□		action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 5,7-10, 15-17 and 24 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) 5,7,8 and 15-17 is/are allowed. 6) Claim(s) 9,10 and 24 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.						
Applicati	on Papers					
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119					
a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority documents application from the International Bureau see the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been receive I (PCT Rule 17.2(a)).	on No d in this National Stage			
	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4)				
3) Inform	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date		atent Application (PTO-152)			

Application/Control Number: 09/730,174

Art Unit: 1644

DETAILED ACTION

- 1. Claims 5, 7-10, 15-17 and 24 are pending.
- 2. The Suspension Prosecution due to a potential interference mailed 9/11/03 has been withdrawn.
- 3. Claims 5, 7-10, 15-17 and 24 are being acted upon in this Office Action.
- 4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless -

- (e) the invention was described in-
- (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or
- (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a). The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).
- 5. Claims 9-10 and 24 are rejected under 35 U.S.C. 102(e) as being anticipated by US Pat No 6,689,566 B1 (filed Jan 14, 1999; PTO 892).

The '566 patent teaches various parathyroid hormone antibodies such as monoclonal and polyclonal antibodies that bind to various human parathyroid hormone peptides such as Val-SER-Glu-ILE-MET (See reference SEQ ID NO: 3, claims 1-4 of '566 patent, in particular) and rat PTH Ala-Val-Ser-Glu-ILE-Gln-LEU-MET (See col. 7, reference SEQ ID NO: 5, col. 4, line 50-54, in particular). The reference antibodies are labeled with a radioisotope, an enzyme, a fluorescent agent or a colorimetric agent (See claim 11 of '566 patent, in particular). The '566 patent further teaches a kit comprising the reference antibodies (See claim 20-24 of '566 patent, in particular) for whole PTH immunoassay (See col. 3, line 47, in particular). A product is a

Application/Control Number: 09/730,174

Art Unit: 1644

product, irrespective of how it is made. The reference antibodies appears to have the same binding specificity as the claimed antibody that binds to human parathyroid hormone peptide SVSEIQLMHNLG (claimed SEQ ID NO: 3) or the rat parathyroid hormone peptide AVSEIQLMHNLG (claimed SEQ ID NO: 5) since the peptide sequences have significant overlapping residues (See underline above). Since the Patent Office does not have the facilities for examining and comparing the antibodies of the instant invention to those of the prior art, the burden is on applicant to show that the prior art antibody is different from the claimed antibody. See In re Best, 562 F.2d 1252, 195 USPQ 430(CCPA 1977). Thus, the reference teachings anticipate the claimed invention.

- 6. Claims 5, 7-8, and 15-17 are allowed.
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong Huynh "NEON" whose telephone number is (571) 272-0846. The examiner can normally be reached Monday through Friday from 9:00 am to 5:30 p.m. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The IFW official Fax number is (703) 872-9306.
- 8. Any information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Phuong N. Huynh, Ph.D.

Patent Examiner

Technology Center 1600

June 14, 2004

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600